Enhanced tumor growth in the NaS1 sulfate transporter null mouse

Cancer Science

Volumn 101, Issue 2, 2010, Pages 369-373

  Dawson, Paul Anthony ^a   Choyce, Allison ^a   Chuang, Christine ^b   Whitelock, John ^b   Markovich, Daniel ^a   Leggatt, Graham Robert ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CARRIER PROTEIN; COLLAGEN; EPITOPE; GLYCOSAMINOGLYCAN; NAS1 SULFATE TRANSPORTER; PROTEOGLYCAN; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL LINE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 75649089337     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01399.x     Document Type: Article

References (40)

1. Markovich D. Physiological roles and regulation of mammalian sulfate transporters. Physiol Rev 2001, 81:1499-534.
2. Mulder GJ, Jakoby WB, Mulder GJ. Sulfation. Conjugation Reactions in Drug Metabolism: An Integrated Approach: Substrates, Co-substrates, Enzymes and Their Interactions In Vivo and In Vitro 1990, 107-61. In, ed, London, Taylor and Francis
3. Sanderson RD, Yang Y, Kelly T, MacLeod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J Cell Biochem 2005, 96:897-905.
4. Novak K. Signalling Cryptic clues about metastasis. Nature Rev Cancer 2002, 2:1-2.
5. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A 2002, 99:568-73.
6. Lai JP, Sandhu DS, Yu C. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47:1211-22.
7. Miyoshi Y, Ando A, Hasegawa S. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clin Cancer Res 2003, 9:2288-93.
8. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PloS One 2007, 2:e392.
9. Miao HQ, Elkin M, Aingorn E, Ishai-Michael R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999, 83:424-31.
10. Florin THJ, Neale G, Goretski S, Cummings JH. The sulfate content of foods and beverages. J Food Compos Anal 1993, 6:140-51.
11. Klassen CD, Boles J. The importance of 3′-phosphoadenosine 5′-phosphosulfate (PAPS) in the regulation of sulfation. FASEB J 1997, 11:404-18.
12. Beck L, Markovich D. The Mouse Na+-Sulfate Cotransporter Gene Nas1: cloning, tissue distribution, gene structure, chromosomal assignment, and transcriptional regulation by vitamin D. J Biol Chem 2000, 275:11880-90.
13. Lee A, Beck L, Markovich D. The human renal sodium sulfate cotransporter (SLC13A1; hNaSi-1) cDNA and gene: organisation, chromosomal localization, and functional characterization. Genomics 2000, 70:354-63.
14. Dawson PA, Beck L, Markovich D. Hyposulfatemia, growth retardation, reduced fertility and seizures in mice lacking a functional NaSi-1 gene. Proc Natl Acad Sci U S A 2003, 100:13704-9.
15. Dawson PA, Gardiner B, Grimmond S, Markovich D. Transcriptional profile reveals altered hepatic lipid and cholesterol metabolism in hyposulfatemic NaS1 null mice. Physiol Genomics 2006, 26:116-24.
16. Dawson PA, Gardiner B, Lee S, Grimmond S, Markovich D. Kidney transcriptome reveals altered steroid homeostasis in NaS1 sulfate transporter null mice. J Steroid Biochem Mol Biol 2008, 112:55-62.
17. Dawson PA, Huxley S, Gardiner B. Impaired intestinal function in the hyposulphataemic NaS1 null mouse. Gut 2009, 58:910-9.
18. Dawson PA, Markovich D. Genetic polymorphisms of human sulfate transporters. Curr Pharmacogenomics 2007, 5:262-74.
19. Lee S, Dawson PA, Hewavitharana AK, Shaw PN, Markovich D. Disruption of NaS1 sulfate transport function in mice leads to enhanced acetaminophen-induced hepatotoxicity. Hepatology 2006, 43:1241-7.
20. Lin KY, Guarnieri FG, Staveley-O'Carroll KF. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996, 56:21-6.
21. Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells. Cancer Res 2003, 63:3058-60.
22. Stewart TJ, Fernando GJ, Frazer IH, Leggatt GR. Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. Immunol Cell Biol 2004, 82:455-61.
23. Chen J, Power KA, Mann J, Cheng A, Thompson LU. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 2007, 232:1071-80.
24. Gomori G. A rapid one-step trichrome stain. Am J Clin Pathol 1950, 20:661-4.
25. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002, 86:1566-77.
26. Blackhall FH, Merry CL, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer 2001, 85:1094-8.
27. Liang G, Miao X, Zhou Y, Tan W, Lin D. A functional polymorphism in the SULT1A1 gene (G638A) is associated with risk of lung cancer in relation to tobacco smoking. Carcinogenesis 2004, 25:773-8.
28. Lv H, Yu G, Sun L, Zhang Z, Zhao X, Chai W. Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma. Oncology 2007, 72:347-56.
29. Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalis SS, Theocharis DA. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003, 35:376-90.
30. Tsara ME, Papageorgacopoulou N, Karavias DD, Theocharis DA. Distribution and changes of glycosaminoglycans in neoplasias of rectum. Anticancer Res 1995, 15:2107-12.
31. Yamori T, Kimura H, Stewart K, Ota DM, Cleary KR, Irimura T. Differential production of high molecular weight sulfated glycoproteins in normal colonic mucosa, primary colon carcinoma, and metastases. Cancer Res 1987, 47:2741-7.
32. Boccia S, Sayed-Tabatabaei FA, Persiani R. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer 2007, 7:206.
33. Chung YT, Hsieh LL, Chen IH. Sulfotransferase 1A1 haplotypes associated with oral squamous cell carcinoma susceptibility in male Taiwanese. Carcinogenesis 2009, 30:286-94.
34. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, Harper PA. Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17:3098-107.
35. Dalhoff K, Buus Jensen K, Enghusen Poulsen H. Cancer and molecular biomarkers of phase 2. Methods Enzymol 2005, 400:618-27.
36. Wang YH, Juang GD, Hwang TI, Shen CH, Shao KY, Chiou HY. Genetic polymorphism of sulfotransferase 1A1, cigarette smoking, hazardous chemical exposure and urothelial cancer risk in a Taiwanese population. Int J Urol 2008, 15:1029-34.
37. Habuchi H, Habuchi O, Kimata K. Sulfation pattern in glycosaminoglycan: does it have a code? Glycoconj J 2004, 21:47-52.
38. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003, 111:487-95.
39. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009, 9:108-22.
40. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev 2008, 18:27-34.